protamine sulphate

CLINICAL USE

Counteract anticoagulant effect of heparin

DOSE IN NORMAL RENAL FUNCTION

Depends on time since stopping IV/subcutaneous heparin and dose of heparin given

PHARMACOKINETICS

Molecular weight :Approx 4500

%Protein binding :1

%Excreted unchanged in urine : No data

Volume of distribution (L/kg) :12.3 litres

half-life – normal/ESRD (hrs) :7.4 minutes/–

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unknown dialysability. Dose as in normal renal function

HD :Unknown dialysability. Dose as in normal renal function

HDF/high flux :Unknown dialysability. Dose as in normal renal function

CAV/VVHD :Unknown dialysability. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

None known

ADMINISTRATION

Reconstition

–

Route

–

Rate of Administration

5 mg/minute

Comments

–

OTHER INFORMATION

Counteracting the anticoagulant effect of heparin during extra-corporeal treatments requires approximately 1.5 mg protamine per 100 IU heparinMost clinicians recommend a dose of 1–1.5 mg protamine sulphate for each 100 units heparin given depending on the length of time since heparin administrationMay be used topically to stop bleeding fistulae

Tags: post-by-auto-php